Navidea Biopharmaceuticals (NAVB) Competitors $0.0006 0.00 (0.00%) As of 11:40 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsOptions ChainSEC FilingsTrendsBuy This Stock NAVB vs. UPC, ADTX, HSTO, HEPA, VAXX, SMFL, SCPS, EVLO, CMRA, and GNCAQShould you be buying Navidea Biopharmaceuticals stock or one of its competitors? The main competitors of Navidea Biopharmaceuticals include Universe Pharmaceuticals (UPC), Aditxt (ADTX), Histogen (HSTO), Hepion Pharmaceuticals (HEPA), Vaxxinity (VAXX), Smart for Life (SMFL), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), and Genocea Biosciences (GNCAQ). These companies are all part of the "pharmaceutical products" industry. Navidea Biopharmaceuticals vs. Universe Pharmaceuticals Aditxt Histogen Hepion Pharmaceuticals Vaxxinity Smart for Life Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Universe Pharmaceuticals (NYSE:UPC) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability. Does the MarketBeat Community prefer UPC or NAVB? Universe Pharmaceuticals and Navidea Biopharmaceuticals both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformUniverse PharmaceuticalsN/AN/ANavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes83100.00% Which has more volatility & risk, UPC or NAVB? Universe Pharmaceuticals has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Is UPC or NAVB more profitable? Company Net Margins Return on Equity Return on Assets Universe PharmaceuticalsN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A Which has stronger earnings & valuation, UPC or NAVB? Universe Pharmaceuticals has higher revenue and earnings than Navidea Biopharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUniverse Pharmaceuticals$26.73M0.01-$6.16MN/AN/ANavidea Biopharmaceuticals$8.13K7.39-$15.18MN/AN/A Do insiders and institutionals believe in UPC or NAVB? 0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to UPC or NAVB? In the previous week, Navidea Biopharmaceuticals had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for Navidea Biopharmaceuticals and 0 mentions for Universe Pharmaceuticals. Universe Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Universe Pharmaceuticals Neutral Navidea Biopharmaceuticals Neutral SummaryUniverse Pharmaceuticals beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Navidea Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAVB vs. The Competition Export to ExcelMetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE ExchangeMarket Cap$60,000.00$2.38B$5.35B$18.68BDividend YieldN/A0.79%5.44%4.16%P/E RatioN/A7.1021.9731.63Price / Sales7.3952.19396.6227.51Price / CashN/A15.7538.2017.53Price / BookN/A3.596.734.36Net Income-$15.18M-$65.73M$3.21B$1.02B7 Day PerformanceN/A3.10%6.42%2.44%1 Month PerformanceN/A-15.77%-5.85%-6.11%1 Year PerformanceN/A-11.68%15.28%1.70% Navidea Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-98.6%$60,000.00$8,126.000.0010UPCUniverse PharmaceuticalsN/A$3.35-4.8%N/A-99.7%$144,000.00$26.73M0.00220ADTXAditxt0.0747 of 5 stars$2.50-13.2%N/A-100.0%$142,000.00$133,985.000.0060Gap DownHigh Trading VolumeHSTOHistogenN/A$0.03flatN/A-91.7%$124,000.00$19,000.00-0.0120HEPAHepion Pharmaceuticals0.2225 of 5 stars$0.38-8.8%N/A-99.6%$54,000.00N/A-0.0920Short Interest ↑Positive NewsHigh Trading VolumeVAXXVaxxinityN/A$0.00-98.0%N/A-99.9%$25,000.00N/A0.0090Upcoming EarningsGap UpSMFLSmart for LifeN/A$0.00-27.8%N/A-100.0%$18,000.00$11.11M0.00110Gap DownSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/A-98.9%$9,000.00N/A0.00120CMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070 Related Companies and Tools Related Companies Universe Pharmaceuticals Competitors Aditxt Competitors Histogen Competitors Hepion Pharmaceuticals Competitors Vaxxinity Competitors Smart for Life Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:NAVB) was last updated on 4/23/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAVB Stock Free NAVB Stock Alerts